Cost-effectiveness Analysis Along the Continuum of HIV Care: How Can We Optimize the Effect of HIV Treatment as Prevention Programs?

Current HIV/AIDS Reports

Volumn 11, Issue 4, 2014, Pages 468-478

  Nosyk, B ^a,b   Krebs, E ^a   Eyawo, O ^a,b   Min, J E ^a   Barrios, R ^a,c   Montaner, J S G ^a,d  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c VANCOUVER COASTAL HEALTH   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cost effective interventions; Highly active antiretroviral therapy (HAART); HIV; HIV care; Treatment as Prevention

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CIRCUMCISION; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; MEDLINE; MORBIDITY; MORTALITY; OPIATE SUBSTITUTION TREATMENT; PRIMARY MEDICAL CARE; PROCESS OPTIMIZATION; PROSTITUTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESOURCE ALLOCATION; REVIEW; COST BENEFIT ANALYSIS; ECONOMICS; HIV INFECTIONS; PATIENT CARE; STANDARDS;

ANTI-RETROVIRAL AGENTS; CONTINUITY OF PATIENT CARE; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS;

EID: 84919427204     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-014-0227-7     Document Type: Review

References (73)

1. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. JAMA. 1998;279(12):930–7.
2. Hogg RS, O’Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349(9061):1294.
3. Braitstein P, Brinkhof M, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817–24.
4. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8(12):e81355.
5. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
6. Nosyk B, Audoin B, Beyrer C, Cahn P, Granich R, Havlir D, et al. Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS. 2013;27(7):1159–65.
7. Wood E, Kerr T, Marshall BDL, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1-RNA concentrations and incidence of HIV-1 among injecting drug users: a prospective cohort study. BMJ. 2009;338:1191–4.
8. Montaner JS. Treatment as prevention—a double hat-trick. Lancet. 2011;378(9787):208–9.
9. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.
10. Nosyk B, Montaner JS, Colley G, Lima VD, Chan K, Heath K, et al. The cascade of HIV care in British Columbia, Canada, 1996–2011: a population-based retrospective cohort study. Lancet Infect Dis. 2014;14(1):40–9. This articles provides a careful characterization of longitudinal changes in engagement with the cascade of HIV care using individual-level data. This mapping of the cascade of care helps understand what further efforts are needed to maximize the individual and public health benefits of Treatment as Prevention.
11. Laxminarayan R, Mills AJ, Breman JG, Measham AR, Alleyne G, Claeson M, et al. Advancement of global health: key messages from the Disease Control Priorities Project. Lancet. 2006;367(9517):1193–208.
12. Freedberg KA, Scharfstein JA, Seage III GR, Losina E, Weinstein MC, Craven DE, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279(2):130–6.
13. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352(6):570–85.
14. Paltiel AD, Weinstein MC, Kimmel AD, Seage III GR, Losina E, Zhang H, et al. Expanded screening for HIV in the United States—an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586–95.
15. Mauskopf J, Kitahata M, Kauf T, Richter A, Tolson J. HIV antiretroviral treatment: early versus later. JAIDS J Acquir Immune Defic Syndr. 2005;39(5):562–9.
16. Farnham PG, Gopalappa C, Sansom SL, Hutchinson AB, Brooks JT, Weidle PJ, et al. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. JAIDS J Acquir Immune Defic Syndr. 2013;64(2):183–9.
17. Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013;27(3):447–58.
18. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. Joint United Nations Programme on HIV/AIDS (UNAIDS); 2013.
19. Schwartländer B, Stover J, Hallett T, Atun R, Avila C, Gouws E, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet. 2011;377(9782):2031–41.
20. UNAIDS. UNAIDS report: ambitious treatment targets: writing the final chapter of the AIDS epidemic: Joint United Nations Programme on HIV/AIDS (UNAIDS)2014. UNAIDS has proposed an ambitious target explicitly focused on the cascade of HIV care of achieving 90 % of people living with HIV/AIDS diagnosed (PWHA), 90 % of those diagnosed on treatment and 90 % of those on treatment achieving viral suppression by 2020.
21. Gold MRSJ, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 1996.
22. Bassett IV, Govindasamy D, Erlwanger AS, Hyle EP, Kranzer K, van Schaik N, et al. Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PLoS ONE. 2014;9(1):e85197.
23. Bos JM, Fennema JS, Postma MJ. Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam. AIDS. 2001;15(15):2031–6.
24. Dowdy DW, Rodriguez RM, Bradley Hare C, Kaplan B. Cost‐effectiveness of targeted human immunodeficiency virus screening in an urban emergency department. Acad Emerg Med. 2011;18(7):745–53.
25. Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, et al. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. JAIDS J Acquir Immune Defic Syndr. 2006;43:S113–8.
26. Fung IC, Guinness L, Vickerman P, Watts C, Vannela G, Vadhvana J, et al. Modelling the impact and cost-effectiveness of the HIV intervention programme amongst commercial sex workers in Ahmedabad, Gujarat, India. BMC Public Health. 2007;7(1):195.
27. Golden MR, Gift TL, Brewer DD, Fleming M, Hogben M, Lawrence JSS, et al. Peer referral for HIV case-finding among men who have sex with men. AIDS. 2006;20(15):1961–8.
28. Gopalappa C, Farnham PG, Hutchinson AB, Sansom SL. Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons. JAIDS J Acquir Immune Defic Syndr. 2012;61(1):99–105.
29. Grabbe KL, Menzies N, Taegtmeyer M, Emukule G, Angala P, Mwega I, et al. Increasing access to HIV counseling and testing through mobile services in Kenya: strategies, utilization and cost-effectiveness. J Acquir Immune Defic Syndr (1999). 2010;54(3):317.
30. Haukoos JS, Campbell JD, Conroy AA, Hopkins E, Bucossi MM, Sasson C, et al. Programmatic cost evaluation of nontargeted opt-out rapid HIV screening in the emergency department. PLoS ONE. 2013;8(12):e81565.
31. Kahn JG, Muraguri N, Harris B, Lugada E, Clasen T, Grabowsky M, et al. Integrated HIV testing, malaria, and diarrhea prevention campaign in Kenya: modeled health impact and cost-effectiveness. PLoS ONE. 2012;7(2):e31316. This is an excellent example of evaluating innovative strategies to diagnose hard-to-reach clients in resource-limited settings. The short term integrated prevention campaign evaluated included HIV testing as well as provision of water filters, bed nets and other services.
32. Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, et al. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Cote d’Ivoire appraisal. PLoS Med. 2009;6(10):e1000173.
33. Marseille E, Giganti MJ, Mwango A, Chisembele-Taylor A, Mulenga L, Over M, et al. Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia. PLoS ONE. 2012;7(12):e51993.
34. Marseille E, Kahn JG, Pitter C, Bunnell R, Epalatai W, Jawe E, et al. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health econ Health Policy. 2009;7(4):229–43.
35. Mathoulin-Pelissier S, Salmi L-R, Fialon P, Salamon R. Cost-effectiveness of testing for human immunodeficiency virus and hepatitis C virus among blood transfusion recipients. Infect Control Hosp Epidemiol. 2003;24(2):132–6.
36. Mulogo E, Batwala V, Nuwaha F, Aden A, Baine O. Cost effectiveness of facility and home based HIV voluntary counseling and testing strategies in rural Uganda. Afr Health Sci. 2013;13(2):423–9. This is an excellent example of evaluating innovative strategies to diagnose hard-to-reach clients in resource-limited settings. Home-based HIV screening in Uganda was found to be cheaper and cost less per infected individual identified compared to facility-based testing.
37. Ownby RL, Waldrop-Valverde D, Jacobs RJ, Acevedo A, Caballero J. Cost effectiveness of a computer-delivered intervention to improve HIV medication adherence. BMC Med Inform Decis Making. 2013;13(1):29.
38. Phillips KA, Fernyak S. The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look. AIDS. 2000;14(14):2159–69.
39. Renaud A, Basenya O, de Borman N, Greindl I, Meyer-Rath G. The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi. AIDS Care. 2009;21(11):1388–94.
40. Ruger JP, Abdallah AB, Ng NY, Luekens C, Cottler L. Cost-effectiveness of interventions to prevent HIV and STDs among women: a randomized controlled trial. AIDS and behavior. 2014:1–11.
41. Sanders GD, Anaya HD, Asch S, Hoang T, Golden JF, Bayoumi AM, et al. Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trial. J Gen Intern Med. 2010;25(6):556–63.
42. Schackman BR, Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, et al. The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug Alcohol Depend. 2013;128(1):90–7. There is an opportunity via community-based substance abuse treatment programs to implement on-site rapid HIV testing. This study, using data from a randomized trial conducted in 12 US community-based substance abuse treatment programs, determined on-site testing to be more efficient than referral for off-site testing.
43. Shrestha RK, Clark HA, Sansom SL, Song B, Buckendahl H, Calhoun CB, et al. Cost-effectiveness of finding new HIV diagnoses using rapid HIV testing in community-based organizations. Public Health Rep. 2008;123 Suppl 3:94.
44. Shrestha RK, Sansom SL, Kimbrough L, Hutchinson AB, Daltry D, Maldonado W, et al. Cost-effectiveness of using social networks to identify undiagnosed HIV infection among minority populations. J Public Health Manag Pract. 2010;16(5):457–64.
45. Spaulding AC, Pinkerton SD, Superak H, Cunningham MJ, Resch S, Jordan AO, et al. Cost analysis of enhancing linkages to HIV care following jail: a cost-effective intervention. AIDS Behav. 2013;17(2):220–6.
46. Sweat M, Gregorich S, Sangiwa G, Furlonge C, Balmer D, Kamenga C, et al. Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania. Lancet. 2000;356(9224):113–21.
47. Thielman NM, Chu HY, Ostermann J, Itemba DK, Mgonja A, Mtweve S, et al. Cost-effectiveness of free HIV voluntary counseling and testing through a community-based AIDS service organization in Northern Tanzania. Am J Public Health. 2006;96(1):114.
48. Tole SP, Sanders GD, Bayoumi AM, Galvin CM, Vinichenko TN, Brandeau ML, et al. Cost-effectiveness of voluntary HIV screening in Russia. Int J STD AIDS. 2009;20(1):46–51.
49. Tran BX, Ohinmaa A, Duong AT, Nguyen LT, Vu PX, Mills S, et al. Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam’s injection-driven HIV epidemics. Drug Alcohol Depend. 2012;125(3):260–6.
50. Tromp N, Siregar A, Leuwol B, Komarudin D, van der Ven A, van Crevel R, et al. Cost-effectiveness of scaling up voluntary counselling and testing in West-Java, Indonesia. Acta Medica Indonesiana. 2013;45(1):17–25.
51. Uhler LM, Kumarasamy N, Mayer KH, Saxena A, Losina E, Muniyandi M, et al. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. PLoS ONE. 2010;5(9):e12747.
52. Walensky RP, Morris BL, Reichmann WM, Paltiel AD, Arbelaez C, Donnell-Fink L, et al. Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department. PLoS ONE. 2011;6(10):e25575.
53. Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men. Medical Decision Making. 2008.
54. Public Health Agency of Canada. Summary: estimates of HIV prevalence and incidence in Canada, 2011, Control CfCDaI;2012.
55. Montaner JS, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV Treatment as Prevention” experience in a Canadian setting. PLoS ONE. 2014;9(2):e87872.
56. Centers for Disease Control and Prevention. HIV surveillance report. Atlanta, GA, U.S. Department of Health and Human Services CfDCaP;2011.
57. Walter L, Zunyou W. Testing and linkage to HIV care in China: a cluster randomized trial (CTN-0056). National Institutes of Health, National Institute on Drug Abuse; 2014.
58. Bärnighausen T, Tanser F, Gqwede Z, Mbizana C, Herbst K, Newell M-L. High HIV incidence in a community with high HIV prevalence in rural South Africa: findings from a prospective population-based study. AIDS. 2008;22(1):139–44.
59. Kohler H-P, Thornton RL. Conditional cash transfers and HIV/AIDS prevention: unconditionally promising? The World Bank Economic Review. 2011.
60. Schierenberg A, van Amsterdam J, van den Brink W, Goudriaan AE. Efficacy of contingency management for cocaine dependence treatment: a review of the evidence. Curr Drug Abuse Rev. 2012;5(4):320–31.
61. Poon AF, Walker LW, Murray H, McCloskey RM, Harrigan PR, Liang RH. Mapping the shapes of phylogenetic trees from human and zoonotic RNA viruses. PLoS ONE. 2013;8(11):e78122.
62. Poon AF, Joy JB, Woods CK, Shurgold S, Colley G, Brumme CJ et al. Population-level phylo genetic analyses quantify the impact of clinical, demographic, and risk factors on variations in HIV transmission rates in British Columbia, Canada. Canadian Association of HIV/AIDS Research 23rd Annual Conference; May 2014; St. John’s, Newfoundland.2014.
63. Klein DJ, Bershteyn A, Eckhoff PA. Dropout and re-enrollment: implications for epidemiological projections of treatment programs. AIDS. 2014;28:S47–59.
64. Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell M-L. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis. 2011;11(12):942–51.
65. Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 2010;51(4):392–400.
66. Gustafson R, Montaner J, Sibbald B. Seek and treat to optimize HIV and AIDS prevention. Can Med Assoc J. 2012;184(18):1971.
67. Kinsler JJ, Sayles JN, Cunningham WE, Mahajan A. Preference for physician vs. nurse-initiated opt-out screening on HIV test acceptance. AIDS Care. 2013;25(11):1442–5.
68. Government of the District of Columbia Department of Health. DC jurisdictional HIV prevention plan 2012–2015. 2012.
69. Government of the District of Columbia. Annual report 2011, Services DoHaH;2012.
70. Centers for Disease Control and Prevention. HIV testing at CDC funded sites, United, States, Puerto Rico and the U.S. Virgin Islands, 2011. Atlanta, GA, Department of Health and Human Services CfDCaP;2013.
71. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost‐effectiveness analysis alongside clinical trials: the ISPOR RCT‐CEA Task Force report. Value Health. 2005;8(5):521–33.
72. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models. PharmacoEconomics. 2000;17(5):461–77.
73. Meyer-Rath G, Over M. HIV treatment as prevention: modelling the cost of antiretroviral treatment—state of the art and future directions. PLoS Med. 2012;9(7):e1001247.